Show simple item record

dc.contributor.authorGudjonsson, JE
dc.contributor.authorKarason, A
dc.contributor.authorAntonsdottir, A
dc.contributor.authorRunarsdottir, EH
dc.contributor.authorHauksson, VB
dc.contributor.authorUpmanyu, R
dc.contributor.authorGulcher, J
dc.contributor.authorStefansson, K
dc.contributor.authorValdimarsson, H
dc.date.accessioned2008-07-23T14:57:58Z
dc.date.available2008-07-23T14:57:58Z
dc.date.issued2003-02-01
dc.date.submitted2008-07-23
dc.identifier.citationBr. J. Dermatol. 2003, 148(2):233-5en
dc.identifier.issn0007-0963
dc.identifier.pmid12588373
dc.identifier.doi10.1046/j.1365-2133.2003.05115.x
dc.identifier.urihttp://hdl.handle.net/2336/32854
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractBACKGROUND: Psoriasis is strongly associated with certain human leucocyte-associated antigens, especially HLA-Cw*0602. Patients who are HLA-Cw*0602 positive have been reported to have more active disease and a younger age at disease onset than HLA-Cw6-negative patients. OBJECTIVES: To ascertain whether there are differences in the clinical features and relative risk between HLA-Cw*0602 homozygous and heterozygous psoriasis patients. METHODS: One thousand and six patients with chronic plaque psoriasis were evaluated clinically and HLA-C typed. In addition, 512 unrelated controls were typed for HLA-C. RESULTS: Of the patients 646 (64.2%) were HLA-Cw*0602 positive, and 68 (6.8%) were homozygous for this allele. Heterozygosity was associated with a relative risk of developing psoriasis of 8.9 compared with 23.1 for the Cw6 homozygous patients. The homozygous patients also had an earlier disease onset (mean 15.0 vs. 17.8 years, P = 0.04). However, the Cw6 homozygotes did not differ from the heterozygotes with respect to disease severity, guttate onset, distribution of plaques, nail changes or any other clinical parameter recorded. CONCLUSIONS: Homozygosity for the gene in the major histocompatibility complex region has a major additive impact on the risk of developing psoriasis and predisposes to an earlier disease onset, but does not have any marked influence on the phenotype or the severity of the disease.
dc.language.isoenen
dc.publisherBlackwell Scientific Publicationsen
dc.relation.urlhttp://dx.doi.org/10.1046/j.1365-2133.2003.05115.xen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAge of Onseten
dc.subject.meshAgeden
dc.subject.meshAllelesen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshGenotypeen
dc.subject.meshHLA-C Antigensen
dc.subject.meshHomozygoteen
dc.subject.meshHumansen
dc.subject.meshInfanten
dc.subject.meshInfant, Newbornen
dc.subject.meshMiddle Ageden
dc.subject.meshPhenotypeen
dc.subject.meshPsoriasisen
dc.subject.meshRisk Factorsen
dc.titlePsoriasis patients who are homozygous for the HLA-Cw*0602 allele have a 2.5-fold increased risk of developing psoriasis compared with Cw6 heterozygotesen
dc.typeArticleen
dc.contributor.departmentDepartment of Immunology, National University Hospital of Iceland, Eiriksgata, 101 Reykjavik, Icelanden
dc.identifier.journalBritish journal of dermatologyen
html.description.abstractBACKGROUND: Psoriasis is strongly associated with certain human leucocyte-associated antigens, especially HLA-Cw*0602. Patients who are HLA-Cw*0602 positive have been reported to have more active disease and a younger age at disease onset than HLA-Cw6-negative patients. OBJECTIVES: To ascertain whether there are differences in the clinical features and relative risk between HLA-Cw*0602 homozygous and heterozygous psoriasis patients. METHODS: One thousand and six patients with chronic plaque psoriasis were evaluated clinically and HLA-C typed. In addition, 512 unrelated controls were typed for HLA-C. RESULTS: Of the patients 646 (64.2%) were HLA-Cw*0602 positive, and 68 (6.8%) were homozygous for this allele. Heterozygosity was associated with a relative risk of developing psoriasis of 8.9 compared with 23.1 for the Cw6 homozygous patients. The homozygous patients also had an earlier disease onset (mean 15.0 vs. 17.8 years, P = 0.04). However, the Cw6 homozygotes did not differ from the heterozygotes with respect to disease severity, guttate onset, distribution of plaques, nail changes or any other clinical parameter recorded. CONCLUSIONS: Homozygosity for the gene in the major histocompatibility complex region has a major additive impact on the risk of developing psoriasis and predisposes to an earlier disease onset, but does not have any marked influence on the phenotype or the severity of the disease.


This item appears in the following Collection(s)

Show simple item record